Lineage Cell Therapeutics, Inc.
LCTX
$0.4817
-$0.0183-3.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -18.61M | -20.11M | -24.19M | -23.66M | -21.49M |
| Total Depreciation and Amortization | 609.00K | 633.00K | 668.00K | 696.00K | 692.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.67M | 3.69M | 4.91M | 5.25M | 3.03M |
| Change in Net Operating Assets | -8.77M | -6.98M | -3.40M | -5.40M | -10.80M |
| Cash from Operations | -23.09M | -22.77M | -22.02M | -23.11M | -28.57M |
| Capital Expenditure | -565.00K | -291.00K | -318.00K | -524.00K | -674.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.74M | 5.09M | 3.35M | 31.51M | 47.12M |
| Cash from Investing | -2.31M | 4.80M | 3.03M | 30.99M | 46.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -54.00K | -53.00K | -52.00K | -54.00K | -54.00K |
| Issuance of Common Stock | 36.11M | 14.30M | 15.13M | 20.83M | 6.71M |
| Repurchase of Common Stock | -23.00K | -222.00K | -222.00K | -222.00K | -236.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -171.00K | 86.00K | 61.00K | -112.00K | 0.00 |
| Cash from Financing | 35.86M | 14.11M | 14.92M | 20.44M | 6.42M |
| Foreign Exchange rate Adjustments | -95.00K | 162.00K | -216.00K | -220.00K | -250.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.36M | -3.69M | -4.28M | 28.10M | 24.06M |
